Polycystic ovary syndrome

Abstract

Polycystic ovary syndrome (PCOS) is a common gynecologic endocrinopathy. The pathogenesis of PCOS is associated with both heredity and environment. PCOS has adverse impacts on female endocrine, reproduction, and metabolism. PCOS can impact women’s reproductive health, leading to anovulatory infertility and higher rate of early pregnancy loss. PCOS has additional metabolic derangements, such as insulin resistance, impaired glucose tolerance, and dyslipidemia. The risks of diabetes, cardiovascular disease, hypertension, metabolic syndrome, and endometrial cancer among PCOS patients are significantly increased as well.

Keywords

polycystic ovary syndrome / genetics / metabolic disturbance

References

[1] AzzizR, WoodsK S, ReynaR, KeyT J, KnochenhauerE S, YildizB O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab, 2004, 89(6): 2745–2749

[2] Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod, 2004, 19(1): 41–47

[3] ChenZ J, ShiY H, ZhaoY R, LiY, TangR, ZhaoL X, ChangZ H. Correlation between single nucleotide polymorphism of insulin receptor gene with polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi, 2004, 39(9): 582–585 (in Chinese)

[4] WangK, YouL, ShiY, WangL, ZhangM, ChenZ J. Association of genetic variants of insulin degrading enzyme with metabolic features in women with polycystic ovary syndrome. Fertil Steril, 2008, 90(2): 378–384

[5] ZhangN, ShiY H, HaoC F, GuH F, LiY, ZhaoY R, WangL C, ChenZ J. Association of +45G15G(T/G) and +276(G/T) polymorphisms in the ADIPOQ gene with polycystic ovary syndrome among Han Chinese women. Eur J Endocrinol, 2008, 158(2): 255–260

[6] DiaoX H, ShiY H, GaoQ, WangL C, TangR, ChenZ J. Relationship between single nucleotide polymorphism-56 of calpain-10 gene and glucose and lipid metabolism in polycystic ovary syndrome patients. Zhonghua Fu Chan Ke Za Zhi, 2008, 43(2): 106–109 (in Chinese)

[7] LeeJ Y, LeeW J, HurS E, LeeC M, SungY A, ChungH W. 111/121 diplotype of Calpain-10 is associated with the risk of polycystic ovary syndrome in Korean women. Fertil Steril, 2009, 92(2): 830–833

[8] HaoC F, BaoH C, ZhangN, GuH F, ChenZ J. Evaluation of association between the CYP11alpha promoter pentannucleotide (TTTTA)n polymorphism and polycystic ovarian syndrome among Han Chinese women. Neuro Endocrinol Lett, 2009, 30(1): 56–60

[9] Van NieuwerburghF, StoopD, CabriP, DhontM, DeforceD, De SutterP. Shorter CAG repeats in the androgen receptor gene may enhance hyperandrogenicity in polycystic ovary syndrome. 2008, 24(12): 669–673

[10] FerkP, PermeM P, TeranN, GersakK. Androgen receptor gene (CAG)n polymorphism in patients with polycystic ovary syndrome, 2008, 90(3): 860–863

[11] ChristopoulosP, MastorakosG, GazouliM, DeligeoroglouE, KatsikisI, Diamanti-KandarakisE, PanidisD, CreatsasG. Study of association of IRS-1 and IRS-2 genes polymorphisms with clinical and metabolic features in women with polycystic ovary syndrome. Is there an impact? Gynecol Endocrinol, 2010<month>March</month><day>9</day> [Epub ahead of print]

[12] FanP, LiuH W, WangX S, ZhangF, SongQ, LiQ, WuH M, BaiH. Identification of the G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene as a risk factor for polycystic ovary syndrome. Hum Reprod, 2010, 25(5): 1288–1294

[13] SproulK, JonesM R, MathurR, AzzizR, GoodarziM O. Association study of four key folliculogenesis genes in polycystic ovary syndrome. BJOG, 2010, 117(6): 756–760

[14] VuralP, DeğirmencioğluS, SaralN Y, AkgülC. Tumor necrosis factor alpha (-308), interleukin-6 (-174) and interleukin-10 (-1082) gene polymorphisms in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol, 2010, 150(1): 61–65

[15] WangK, WangL, ZhaoY, ShiY, WangL, ChenZ J. No association of the Arg51Gln and Leu72Met polymorphisms of the ghrelin gene and polycystic ovary syndrome. Hum Reprod, 2009, 24(2): 485–490

[16] ZhengQ, ShiY, YangZ, XuX, WangL, XueF, GuH F, ChenZ J. Family-based association study of the MCF 2L2 gene and polycystic ovary syndrome. Gynecol Obstet Invest, 2009, 68(3): 171–173

[17] EwensK G, StewartD R, AnkenerW, UrbanekM, McAllisterJ M, ChenC, BaigK M, ParkerS C, MarguliesE H, LegroR S, DunaifA, StraussJ F 3rd, SpielmanR S. Family-based analysis of candidate genes for polycystic ovary syndrome. J Clin Endocrinol Metab, 2010, 95(5): 2306–2315

[18] AzzizR, CarminaE, DewaillyD, Diamanti-KandarakisE, Escobar-MorrealeH F, FutterweitW, JanssenO E, LegroR S, NormanR J, TaylorA E, WitchelS F. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril, 2009, 91(2): 456–488

[19] HomburgR. Androgen circle of polycystic ovary syndrome. Hum Reprod, 2009, 24(7): 1548–1555

[20] BlankS K, McCartneyC R, HelmK D, MarshallJ C. Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty. Semin Reprod Med, 2007, 25(5): 352–359

[21] HomburgR. Pregnancy complications in PCOS. Best Pract Res Clin Endocrinol Metab, 2006, 20(2): 281–292

[22] HeijnenE M, EijkemansM J, HughesE G, LavenJ S, MacklonN S, FauserB C. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update, 2006, 12(1): 13–21

[23] BoomsmaC M, EijkemansM J C, HughesE G, VisserG H, FauserB C, MacklonN S. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update, 2006, 12(6): 673–683

[24] VrbikovaJ, HainerV. Obesity and polycystic ovary syndrome. Obes Facts, 2009, 2(1): 26–35

[25] CupistiS, KajaiaN, DittrichR, DuezenliH, W BeckmannM, MuellerA. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome. Eur J Endocrinol, 2008, 158(5): 711–719

[26] WagenknechtL E, LangefeldC D, ScherzingerA L, NorrisJ M, HaffnerS M, SaadM F, BergmanR N. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes, 2003, 52(10): 2490–2496

[27] GlueckC J, PapannaR, WangP, GoldenbergN, Sieve-SmithL. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism, 2003, 52(7): 908–915

[28] PalombaS, FalboA, RussoT, OrioF, TolinoA, ZulloF. Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. Hum Reprod, 2010, 25(4): 1005–1013

[29] ToprakS, YönemA, CakirB, GülerS, AzalO, OzataM, CorakçiA. Insulin resistance in nonobese patients with polycystic ovary syndrome. Horm Res, 2001, 55(2): 65–70

[30] DunaifA, SegalK R, FutterweitW, DobrjanskyA. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes, 1989, 38(9): 1165–1174

[31] ApridonidzeT, EssahP A, IuornoM J, NestlerJ E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab, 2005, 90(4): 1929–1935

[32] DokrasA. Cardiovascular disease risk factors in polycystic ovary syndrome. Semin Reprod Med, 2008, 26(1): 39–44

[33] RochaM P, MaranhãoR C, SeydellT M, BarcellosC R, BaracatE C, HayashidaS A, BydlowskiS P, MarcondesJ A. Metabolism of triglyceride-rich lipoproteins and lipid transfer to high-density lipoprotein in young obese and normal-weight patients with polycystic ovary syndrome. Fertil Steril, 2010, 93(6): 1948–1956

[34] SoaresE M, AzevedoG D, GadelhaR G, LemosT M, MaranhãoT M. Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome. Fertil Steril, 2008, 89(3): 649–655

[35] LoJ C, FeigenbaumS L, YangJ, PressmanA R, SelbyJ V, GoA S. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab, 2006, 91(4): 1357–1363

RIGHTS & PERMISSIONS

2014 Higher Education Press and Springer-Verlag Berlin Heidelberg